Sinntaxis in Lund has been awarded SEK 500,000 under the SME instrument phase 1 program within the EU Horizon 2020 framework. The grant money will be used to advance the business plan and the regulatory work to initiate a phase II clinical trial in stroke recovery.
Sinntaxis recently secured an exclusive option to substance AZD2066, an mGluR5 NAM molecule that binds to glutamate receptor 5, that previously was developed by AstraZeneca in other CNS indications.
Sinntaxis is developing a potentially pioneering treatment helping stroke survivors recover brain function. There is currently no drug treatment available to help stroke patients recover brain function. Patients are currently restricted to rehabilitation therapy, particularly physiotherapy and speech therapy.
Sinntaxis has validated preclinically a class of drugs that blocks a key receptor in the brain and aids re-learning. The company has applied for a patent for use of this class, mGluR5 NAMs, in stroke recovery and plans to start a phase II trial in 2020.
“We are delighted that we have been awarded this Horizon 2020 grant. There is a very large medical need to help stroke survivors recover lost brain function and our work towards developing the first drug for this purpose in the clinic is starting to attract attention”, says Michael Oredsson, CEO of Sinntaxis.
Sinntaxis is a member of SmiLe Incubator, a life science business incubator that helps entrepreneurs to commercialize their ideas by offering business advisory services, laboratories and network. Sinntaxis is also a portfolio company of LU Holding. www.smileincubator.life www.innovation.lu.se
For information contact: Michael Oredsson, CEO, Sinntaxis AB, +46 70-7188930, firstname.lastname@example.org
About Horizon 2020: Horizon 2020 is the largest research and innovation program in the EU with nearly 80 billion euros in funding, available for 7 years (2014-2020). The program emphasizes high-quality science, industrial management and meeting social challenges. The goal is to ensure that Europe produces world-class science, removes barriers to innovation and facilitates the public and private sector to work together for innovation.
About stroke: A stroke causes blood flow to the brain to be blocked as a result of a blood clot or bleeding, causing cell death. Stroke is a growing problem, not least as a consequence of an aging population. Globally, 17 million individuals suffer a stroke annually and one third of this population will subsequently depend on institutional or home care. Stroke must be treated with surgery or thrombolysis within a few hours to restore blood flow. Less than 15 percent of stroke sufferers in prosperous countries and less than one percent in developing countries, receive such injury-reducing treatment in time.
About Sinntaxis AB: Sinntaxis is a privately-owned company developing new drugs to facilitate rehabilitation of stroke patients. The company has patented its discoveries in relation to the positive effects of so-called mGlur5 modulators on the brain's ability to compensate for stroke injuries. A drug candidate, that has demonstrated good pharmacokinetic properties and a good safety profile in Phase 2 studies in another patient population, will be developed as a new potentially pioneering treatment to minimise the debilitating and often lifelong consequences of stroke. Sinntaxis plans to initiate a Phase 2 study in stroke patients in 2019/2020. The company has its head office at the SmiLe Incubator in Lund, Sweden, and is owned by, inter alia, LU Holding AB.